Le site du DES d'oncologie de Toulouse


CheckMate 816 : Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Pneumologie - Publié le 13/04/2022 par Corentin Pasquier

In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery.

Source : NEJM Avril 2022